Jeffrey A. Leerink

Chairman and CEO

Jeffrey A. Leerink founded Leerink Swann in 1995, creating the first independent healthcare research firm providing investors with direct access to analysts, physicians and medical professionals. In 1999, the firm ranked 30^th in Inc. magazine's "America's 500 Fastest-Growing Private Companies." Under Mr. Leerink's leadership, the firm has grown to become the premier healthcare investment bank, providing investment banking, institutional sales and trading, equity research, asset management and strategic advisory services for institutional, life sciences and high-net-worth clients. Every year since 2001, Institutional Investor has named Leerink Swann “Best of the Boutiques” in several healthcare categories.

Mr. Leerink sits on the Board of Directors of Humedica, Inc., a next generation clinical informatics company, and is a member of the Board of Fellows for Harvard Medical School. He also actively supports a number of charitable organizations and sits on the board of Big Brothers of Massachusetts Bay. In addition, Mr. Leerink is a member of the International Game Fishing Association. Mr. Leerink formerly served as an Alumni Advisor to The Union College Board of Trustees. He was born in Massachusetts, and received his B.A. in Economics from Union College.

Daniel B. Dubin, M.D

Vice Chairman of Leerink Swann and Founder of MEDACorp

Daniel B. Dubin has been an advisor to institutional investors and corporate life sciences clients since 1996. Dr. Dubin is also a member of the Management Committee and Chair of the Commitment Committee at Leerink Swann. He was an instructor in Dermatology at Harvard Medical School and has held staff appointments at the Brigham and Women's Hospital and Dana Farber Cancer Institute. While at Brigham and Women's Hospital, he served as Ambulatory Medical Director of Clinical Dermatology and as a member of the Clinical Executive Committee.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in internal medicine and a residency in Dermatology at Massachusetts General Hospital. He has published over 30 manuscripts in medical journals and textbooks and performed a NIH training fellowship at the Harvard Skin Disease Research Center. He serves as a Director of Leerink Swann, Eleme Medical, and NanoBio Corporation. He is the former Chairman of MetaWorks, Inc.

James Boylan

Senior Managing Director, Head of Investment Banking

James (Jim) Boylan joined Leerink Swann in 2009 as Senior Managing Director, Head of Investment Banking. Mr. Boylan brings 20 years of experience to the Firm. He built his investment banking career at Merrill Lynch over the past 12 years both as an M&A specialist and a healthcare origination banker with a focus on life sciences, medical device and healthcare services companies. 

Mr. Boylan's deal resume includes more than 80 completed transactions where he helped clients complete the full spectrum of M&A and financing transactions.  Recent notable transactions include advising Celgene on its acquisition of Pharmion and advising Lifecell on its sale to Kinetic Concepts.

Mr. Boylan earned his M.B.A. from Columbia University and a B.S. from Lehigh University.

Joseph Gentile

Chief Administrative Officer

Joseph Gentile joined the Firm in 2007 as Chief Administrative Officer. Mr. Gentile was formerly CFO, Global Investment Bank at Lehman Brothers, where he directed the accounting and financial needs within the Fixed Income division, the largest operating division of Lehman Brothers.

Prior to that, he served as CFO of the Global Corporate and Investment Bank at Bank of America, where he led the Capital Markets Division. Previously, Mr. Gentile spent more than 10 years with J.P. Morgan in various financial management positions, including Global Head of Financial Risk Management. He holds a B.S. in accounting and MBA in finance from St. John's University.

Timothy A.G. Gerhold

General Counsel

Timothy Gerhold joined the Firm in 2006 as its General Counsel and Senior Managing Director of the Compliance and Legal Group. Prior to joining the Firm, Mr. Gerhold was the General Counsel and Head of Compliance of BancBoston Capital, one of the largest bank-affiliated private equity groups in the United States. Before that, Mr. Gerhold held a number of positions in the Law Office of BankBoston Financial Corporation, including Group Head of the Capital Markets Group and Group Head of the Financial Services Group. Previously, Mr. Gerhold practiced law at Goodwin Proctor LLP. Mr. Gerhold received his B.A. from Carleton College, and his J.D. from Yale Law School.

Devon Baranski

Senior Managing Director, Head of Private and Corporate Client Services

Devon Baranski joined the Firm in 2010 as Head of Private and Corporate Client Services.  Most recently, he was responsible for the Western Region of Merrill Lynch's Private Banking and Investment Group (PBIG).  Devon also had national responsibilities for Marketing and Client Coverage within PBIG.  Devon was responsible for opening Merrill Lynch's first PBIG office in Los Angeles in June of 2001, which became the flagship office for Merill's PBIG efforts.  Devon received his B.A. from Yale University. 

Michael Jenkins

Senior Managing Director, Head of Leerink Swann Strategic Advisors

John McPhee

Managing Director, Head of Private Client Group

John McPhee has been with Leerink Swann since its inception in 1995.  In 2004, Mr. McPhee was named the Head of Private Client Service and in 2006 launched the Middle Market sales effort at Leerink Swann. Mr. McPhee is a Registered Securities Principal and a Registered Options Principal. He is a graduate of Bentley College with a B.S. in Finance.
 
 
 

John L. Sullivan, CFA

Managing Director, Head of Equity Research

John L. Sullivan is Director of Research at Leerink Swann and its Healthcare Investment Strategist. As a sector analyst, Mr. Sullivan recently ranked #3 in The Wall Street Journal’s 2008 “Best on the Street” analysts’ survey. As a stock picker in 2007, he earned a #2 ranking among the life sciences tools and services analysts ranked by Starmine in Forbes.com and a #3 ranking among the same group for accuracy of his earnings estimates. Previously, Mr. Sullivan was a Vice President, Senior Equity Research Analyst, Life Sciences, at Stephens Inc. where his primary focus was on companies possessing enabling technologies for health care-related products for research and drug discovery. Mr. Sullivan, a Chartered Financial Analyst, received his Bachelor of Science degree from Boston University and an MBA from J.L. Kellogg Graduate School of Management at Northwestern University.

Robert Leerink

Managing Director, Head of Institutional Sales

Robert Leerink has been with Leerink Swann since its inception in 1995. He has been a Managing Director in Leerink Swann's Institutional Sales group since 2000. Prior to joining Institutional Sales, Mr. Leerink led the Private Client Services group at Leerink Swann. He began his career in the private client services division of Fector Detwiler. Mr. Leerink holds a bachelor's degree from Babson College.

Mark Rathjen

Managing Director, Head of Institutional Trading

Mark Rathjen has been trading securities for over 15 years. Prior to joining Leerink Swann in 2005, Mr. Rathjen was VP Equities at Goldman Sachs. Previously, he served as Senior Vice President and Trading Desk Manager at Spear, Leeds & Kellogg Capital Markets. Mr. Rathjen began his career at NYSE specialist firm, Ernst Holmes. He holds a B.A. in Business from St. Bonaventure University.